AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23559220 — intervention group
Group type: COMPARATOR
Intervention: olanzapine
Number of subjects: 80
Study 21327805 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 100
Study 21327805 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 2.5 μg/kg
Number of subjects: 100
Study 21327805 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.5 mg/kg
Number of subjects: 100
Study 21327805 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 0.1 mg/kg
Number of subjects: 100
Study 19930021 — intervention group
Group type: EXPERIMENTAL
Intervention: Day/Residential services (n = 42)
Number of subjects: 184
Study 19930021 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient services (n = 37)
Number of subjects: 184
Study 16896874 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcurrent skin patch (MCT) plus tramadol hydrochloride
Number of subjects: 24
Study 16896874 — intervention group
Group type: COMPARATOR
Intervention: Tramadol hydrochloride (control)
Number of subjects: 24
Study 16388069 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g/day ethyl-EPA
Number of subjects: 75
Study 16388069 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g/day ethyl-EPA
Number of subjects: 75
Study 16388069 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 12748973 — intervention group
Group type: EXPERIMENTAL
Intervention: GP+EX (Group Psychotherapy plus Home-based Exercise)
Number of subjects: 108
Study 12748973 — intervention group
Group type: COMPARATOR
Intervention: GP (Group Psychotherapy)
Number of subjects: 108
Study 11098244 — intervention group
Group type: EXPERIMENTAL
Intervention: LHRH agonists
Number of subjects: 184500
Study 11098244 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined androgen blockade
Number of subjects: 184500
Study 11098244 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsteroidal antiandrogen
Number of subjects: 184500
Study 11098244 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary androgen suppression initiated at diagnosis
Number of subjects: 184500
Study 8735863 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP), 800 micrograms daily
Number of subjects: 16
Study 8735863 — intervention group
Group type: COMPARATOR
Intervention: Bronchodilators only
Number of subjects: 16
Study 1768820 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium thiopental (3 mg/kg)
Number of subjects: 44
Study 1768820 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate (0.15 mg/kg)
Number of subjects: 44
Study 1768820 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (1.5 mg/kg)
Number of subjects: 44
Study 1768820 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.15 mg/kg)
Number of subjects: 44
Study 6803909 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses (regimen I)
Number of subjects: 91
Study 6803909 — intervention group
Group type: COMPARATOR
Intervention: Very high doses (regimen II)
Number of subjects: 91
Study 30596649 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear-spatial materials (discrete squares arranged in rows)
Number of subjects: 29
Study 30596649 — intervention group
Group type: COMPARATOR
Intervention: Irregular materials (pictures of stars arranged in random arrays)
Number of subjects: 29
Study 30596649 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear-spatial materials
Number of subjects: 29
Study 27912940 — intervention group
Group type: EXPERIMENTAL
Intervention: Panax ginseng and Salvia miltiorrhiza supplementation
Number of subjects: 23
Study 27912940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 27912940 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric resistance training (both groups)
Number of subjects: 23
Study 26107836 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage and electromechanical pumping
Number of subjects: 16
Study 22417254 — intervention group
Group type: COMPARATOR
Intervention: Ingenol mebutate gel (0.015% for face and scalp, 0.05% for trunk and extremities), self-applied to a 25-cm² contiguous field once daily for 3 consecutive days (face/scalp) or 2 consecutive days (trunk/extremities)
Number of subjects: 0
Study 22417254 — intervention group
Group type: COMPARATOR
Intervention: Ingenol mebutate gel
Number of subjects: 0
Study 21086591 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetolaser therapy in combination with whole body iodine‐bromide‐sodium chlorine baths, physical exercises, and massage
Number of subjects: 67
Study 19014552 — intervention group
Group type: EXPERIMENTAL
Intervention: Education program (structured dialogue conveying information about pathophysiology, pharmacological and non‐pharmacological treatment of GERD, patients' rights and use of healthcare)
Number of subjects: 211
Study 19014552 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 211
Study 19014552 — intervention group
Group type: EXPERIMENTAL
Intervention: Education program (knowledge test score)
Number of subjects: 211
Study 15724034 — intervention group
Group type: EXPERIMENTAL
Intervention: Low supplementation throughout (group LL)
Number of subjects: 119
Study 15724034 — intervention group
Group type: EXPERIMENTAL
Intervention: High supplementation throughout (group HH)
Number of subjects: 119
Study 15724034 — intervention group
Group type: COMPARATOR
Intervention: Low until day 10 and then high (group LH)
Number of subjects: 119
Study 11842293 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific immunotherapy for 3 years
Number of subjects: 205
Study 11842293 — intervention group
Group type: COMPARATOR
Intervention: Control group (open control)
Number of subjects: 205
Study 12198784 — intervention group
Group type: EXPERIMENTAL
Intervention: Phoneme sharing condition (first phoneme shared)
Number of subjects: 0
Study 12198784 — intervention group
Group type: EXPERIMENTAL
Intervention: Phoneme sharing condition (last phoneme shared)
Number of subjects: 0
Study 12198784 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual route cascaded model of reading
Number of subjects: 0
Study 7475039 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 128
Study 7475039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 7475039 — intervention group
Group type: COMPARATOR
Intervention: Sober
Number of subjects: 128
Study 1723461 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (20 mg once daily for 4 months)
Number of subjects: 52
Study 1723461 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (20 mg once daily for 4 months)
Number of subjects: 52
Study 1723461 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 52
Study 1723461 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 52
Study 1723461 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine and Enalapril
Number of subjects: 52
Study 6756533 — intervention group
Group type: COMPARATOR
Intervention: iopamidol (Niopam)
Number of subjects: 50
Study 6756533 — intervention group
Group type: EXPERIMENTAL
Intervention: sodium meglumine ioxaglate (Hexabrix)
Number of subjects: 50
Study 30422259 — intervention group
Group type: EXPERIMENTAL
Intervention: DIL intervention (depression in later life intervention)
Number of subjects: 181
Study 30422259 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 181
Study 30422259 — intervention group
Group type: EXPERIMENTAL
Intervention: DIL intervention
Number of subjects: 181
Study 28632867 — intervention group
Group type: EXPERIMENTAL
Intervention: WIC program plus a 12-month primarily internet-based weight loss program
Number of subjects: 371
Study 28632867 — intervention group
Group type: COMPARATOR
Intervention: WIC program (standard care group)
Number of subjects: 371
Study 25801231 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudomonas aeruginosa preparation (PAP)
Number of subjects: 72
Study 23950601 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 46
Study 23950601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 21078681 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan 10-mg ODT
Number of subjects: 102
Study 21078681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 19647431 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-masking
Number of subjects: 4
Study 19647431 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-observer reliability
Number of subjects: 4
Study 19647431 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-masking
Number of subjects: 4
Study 18042619 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional pacing at 70 min(‐1)
Number of subjects: 372
Study 18042619 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive pacing with four therapies
Number of subjects: 372
Study 18042619 — intervention group
Group type: COMPARATOR
Intervention: Single rate pacing at 40 min(‐1)
Number of subjects: 372
Study 15058255 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmyocardial laser revascularization (TMLR) alone
Number of subjects: 62
Study 15058255 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CABG and TMLR (CABG/TMLR group)
Number of subjects: 62
Study 15058255 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 62
Study 10736287 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous T(3) at 0.4 microg/kg
Number of subjects: 28
Study 10736287 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous T(3) at 0.6 microg/kg
Number of subjects: 28
Study 10736287 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous T(3) at 0.8 microg/kg
Number of subjects: 28
Study 10736287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 8725414 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic CPB (rectal temperature 27 to 28 degrees C)
Number of subjects: 30
Study 8725414 — intervention group
Group type: COMPARATOR
Intervention: Normothermic CPB (rectal temperature > 36 degrees C)
Number of subjects: 30
Study 8725414 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic CPB
Number of subjects: 30
Study 8725414 — intervention group
Group type: COMPARATOR
Intervention: Normothermic CPB
Number of subjects: 30
Study 1446756 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical timolol
Number of subjects: 59
Study 3967835 — intervention group
Group type: EXPERIMENTAL
Intervention: Double blind placebo controlled food challenges
Number of subjects: 49
Study 3967835 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 29524287 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatide™
Number of subjects: 0
Study 29524287 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study 28923492 — intervention group
Group type: EXPERIMENTAL
Intervention: ECA/Kardia intervention (smartphone-based Embodied Conversational Agent and Alive Cor Kardia Mobile heart rhythm monitor)
Number of subjects: 180
Study 28923492 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (symptom and adherence journal)
Number of subjects: 180
Study 25808572 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam 8 mg
Number of subjects: 57
Study 25808572 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 400 mg
Number of subjects: 57
Study 22407959 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-person expressive writing
Number of subjects: 0
Study 22407959 — intervention group
Group type: COMPARATOR
Intervention: First-person expressive writing
Number of subjects: 0
Study 20711135 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg/day of alpha lipoic acid for two months
Number of subjects: 120
Study 20711135 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg/day of gabapentin for two months
Number of subjects: 120
Study 20711135 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 600 mg/day of alpha lipoic acid and 300 mg/day of gabapentin for two months
Number of subjects: 120
Study 20711135 — intervention group
Group type: COMPARATOR
Intervention: 100 mg/day of cellulose starch for two months
Number of subjects: 120
Study 19907100 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 2 mg/day for 12 months
Number of subjects: 45
Study 17115015 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT/LCT emulsion (50:50)
Number of subjects: 24
Study 17115015 — intervention group
Group type: COMPARATOR
Intervention: LCT emulsion (100%)
Number of subjects: 24
Study 15531028 — intervention group
Group type: EXPERIMENTAL
Intervention: Priorix
Number of subjects: 620
Study 15531028 — intervention group
Group type: COMPARATOR
Intervention: RORVax
Number of subjects: 620
Study 11557159 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.1‐0.5 mg/kg)
Number of subjects: 35
Study 11557159 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.3 mg/kg)
Number of subjects: 35
Study 11557159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 11557159 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 35
Study 9500318 — intervention group
Group type: EXPERIMENTAL
Intervention: sublingual/oral immunotherapy
Number of subjects: 20
Study 9500318 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 8719303 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH (1 microgram/kg/bw iv bolus at 0 and 120 min)
Number of subjects: 6
Study 8719303 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH followed by hexarelin (1 microgram/kg/bw iv bolus at 0 and 120 min)
Number of subjects: 6
Study 8719303 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexarelin (1 microgram/kg/bw iv bolus at 0 and 120 min)
Number of subjects: 6
Study 8719303 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH (second bolus)
Number of subjects: 6
Study 8719303 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexarelin (after first GHRH bolus)
Number of subjects: 6
Study 8719303 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated hexarelin administration
Number of subjects: 6
Study 2703387 — intervention group
Group type: EXPERIMENTAL
Intervention: Misonidazole (MISO) 1 g/m2/d with brachytherapy for ENT tumors
Number of subjects: 46
Study 2703387 — intervention group
Group type: EXPERIMENTAL
Intervention: Misonidazole (MISO) 1 g/m2/d with hypofractionated external radiotherapy for breast cancer
Number of subjects: 46
Study 2703387 — intervention group
Group type: EXPERIMENTAL
Intervention: Misonidazole (MISO) 1 g/m2/d with hypofractionated external radiotherapy for large ENT tumors
Number of subjects: 46
Study 329375 — intervention group
Group type: EXPERIMENTAL
Intervention: Secretolytic agents
Number of subjects: 8
Study 329375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31971034 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsoriatic drugs (10 drugs including 3 oral medications and 7 biologic agents)
Number of subjects: 0
Study 31971034 — intervention group
Group type: EXPERIMENTAL
Intervention: PASI alone
Number of subjects: 0
Study 31971034 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of treatment alone
Number of subjects: 0
Study 30484743 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting Wisely web-based modules coupled with text messaging
Number of subjects: 37
Study 30484743 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 37
Study 29137509 — intervention group
Group type: EXPERIMENTAL
Intervention: Research abstract from a high-income country
Number of subjects: 347
Study 29137509 — intervention group
Group type: COMPARATOR
Intervention: Research abstract from a low-income country
Number of subjects: 347
Study 25999201 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention Intervention (RI)
Number of subjects: 26
Study 25999201 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed Retention Intervention (DRI)
Number of subjects: 26
Study 25999201 — intervention group
Group type: COMPARATOR
Intervention: Control (NFP as usual)
Number of subjects: 26
Study 24263878 — intervention group
Group type: EXPERIMENTAL
Intervention: Hatha yoga exercises (6 individually-applied sessions with ongoing home practice)
Number of subjects: 45
Study 24263878 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 45
Study 22070722 — intervention group
Group type: EXPERIMENTAL
Intervention: Differentiated muscle training exercises under physiotherapeutic instruction, followed by independent performance by patients.
Number of subjects: 60
Study 22070722 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy with respiratory therapy and 'hot roll' treatment on radiation treatment days.
Number of subjects: 60
Study 19238697 — intervention group
Group type: EXPERIMENTAL
Intervention: Aban Aya prevention curriculum delivered by trained parent educators
Number of subjects: 0
Study 16278069 — intervention group
Group type: EXPERIMENTAL
Intervention: Aceclofenac administered preoperatively (2 tablets of 100 mg taken orally 1h before surgery)
Number of subjects: 40
Study 16278069 — intervention group
Group type: COMPARATOR
Intervention: Aceclofenac administered postoperatively (2 tablets of 100 mg taken orally in the early postoperative period)
Number of subjects: 40
Study 12499964 — intervention group
Group type: EXPERIMENTAL
Intervention: Triangular osteosynthesis
Number of subjects: 12
Study 12499964 — intervention group
Group type: COMPARATOR
Intervention: Iliosacral screw fixation
Number of subjects: 12
Study 10476974 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric training (15 minutes of plyometrics supplemented to 1.25 hours of swimming, 3 times per week for 20 weeks)
Number of subjects: 38
Study 10476974 — intervention group
Group type: COMPARATOR
Intervention: Control group (1.5 hours of swimming, 3 times per week for 20 weeks)
Number of subjects: 38
Study 8961972 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen therapy beyond 5 years
Number of subjects: 194
Study 8961972 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 194
Study 8961972 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen therapy for estrogen receptor-positive tumors
Number of subjects: 194
Study 1842806 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose oral quinine (1050 mg in two divided doses daily for five days)
Number of subjects: 0
Study 7129168 — intervention group
Group type: EXPERIMENTAL
Intervention: Didactic training (imagery techniques taught)
Number of subjects: 0
Study 7129168 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving training (practical solutions for everyday difficulties)
Number of subjects: 0
Study 7129168 — intervention group
Group type: COMPARATOR
Intervention: Wait list (control group)
Number of subjects: 0
Study 3907823 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine, 18-150 mg/day (mean, 72.5)
Number of subjects: 15
Study 30048858 — intervention group
Group type: EXPERIMENTAL
Intervention: SAA, NO, and CRP levels in septic shock (A) group
Number of subjects: 100
Study 30048858 — intervention group
Group type: EXPERIMENTAL
Intervention: NO levels in septic shock (A) group
Number of subjects: 100
Study 30048858 — intervention group
Group type: EXPERIMENTAL
Intervention: SAA, CRP, and NO levels in death (D) group
Number of subjects: 100
Study 30048858 — intervention group
Group type: EXPERIMENTAL
Intervention: APACHE II score in death (D) group
Number of subjects: 100
Study 30048858 — intervention group
Group type: EXPERIMENTAL
Intervention: SAA, NO, and CRP levels
Number of subjects: 100
Study 27283947 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinpocetine 30 mg intravenously once daily for 7 days
Number of subjects: 610
Study 27283947 — intervention group
Group type: COMPARATOR
Intervention: Control group (cytidine disphosphate choline + aspirin/clopidogrel)
Number of subjects: 610
Study 27283947 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinpocetine
Number of subjects: 610
Study 24876712 — intervention group
Group type: EXPERIMENTAL
Intervention: Full strength formocresol
Number of subjects: 90
Study 24876712 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:5 diluted formocresol
Number of subjects: 90
Study 24876712 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:25 diluted formocresol
Number of subjects: 90
Study 22652556 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcifediol (Hidroferol®, 1 ampoule: 266 μg) administered weekly after HD for 6 doses
Number of subjects: 59
Study 22652556 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients (controls)
Number of subjects: 59
Study 20492442 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etch composite cement (Panavia Fluoro cement) applied by dental students
Number of subjects: 16
Study 20492442 — intervention group
Group type: COMPARATOR
Intervention: Self-etch composite cement (Panavia Fluoro cement) applied by trained dentists
Number of subjects: 16
Study 18818572 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin + cilostazol
Number of subjects: 20
Study 18818572 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 20
Study 15879923 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg/day vaginal ring
Number of subjects: 174
Study 15879923 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/day vaginal ring
Number of subjects: 174
Study 15879923 — intervention group
Group type: COMPARATOR
Intervention: 0.0075 mg/day vaginal ring (active comparator)
Number of subjects: 174
Study 12915827 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 to 20 mg)
Number of subjects: 187
Study 12915827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study 10690149 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-prepared heparinized syringes
Number of subjects: 30
Study 10690149 — intervention group
Group type: COMPARATOR
Intervention: Commercially manufactured dry balanced heparinized syringes
Number of subjects: 30
Study 8759656 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.i.d.
Number of subjects: 19
Study 8759656 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 40 mg qAM
Number of subjects: 19
Study 8759656 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 40 mg qPM
Number of subjects: 19
Study 8759656 — intervention group
Group type: COMPARATOR
Intervention: All regimens of omeprazole 40 mg
Number of subjects: 19
Study 1681275 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal letters to patients outlining their cancer consultation
Number of subjects: 0